Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T
P Porcari1,2, M E Hegi3, H Lei4,5
1Centre for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. paola.porcari@ncl.ac.uk.
Abstract:
Glioma models have provided important insights into human brain cancers. Among the investigative tools, MRI has allowed their characterization and diagnosis. In this study, we investigated whether diffusion MRI might be a useful technique for early detection and characterization of slow-growing and diffuse infiltrative gliomas, such as the proposed new models, LN-2669GS and LN-2540GS glioma sphere xenografts. Tumours grown in these models are not visible in conventional T2 -weighted or contrast-enhanced T1 -weighted MRI at 14.1 T. Diffusion-weighted imaging and diffusion tensor imaging protocols were optimized for contrast by exploring long diffusion times sensitive for probing the microstructural alterations induced in the normal brain by the slow infiltration of glioma sphere cells. Compared with T2 -weighted images, tumours were properly identified in their early stage of growth using diffusion MRI, and confirmed by localized proton MR spectroscopy as well as immunohistochemistry. The first evidence of tumour presence was revealed for both glioma sphere xenograft models three months after tumour implantation, while no necrosis, oedema or haemorrhage were detected either by MRI or by histology. Moreover, different values of diffusion indices, such as mean diffusivity and fractional anisotropy, were obtained in tumours grown from LN-2669GS and LN-2540GS glioma sphere lines. These observations highlighted diverse tumour microstructures for both xenograft models, which were reflected in histology. This study demonstrates the ability of diffusion MRI techniques to identify and investigate early stages of slow-growing, invasive tumours in the mouse brain, thus providing a potential imaging biomarker for early detection of tumours in humans.
Insights
Diffusion MRI can detect early-stage, slow-growing gliomas in mice that are invisible to conventional MRI. This technique offers a potential imaging biomarker for early tumor detection in humans.
Area of Science:
- Neuro-oncology
- Medical Imaging
Background:
- Glioma models are crucial for understanding human brain cancers.
- Conventional MRI techniques (T2-weighted, contrast-enhanced T1-weighted) struggle to detect early-stage, slow-growing gliomas.
- Diffusion MRI offers potential for improved detection of infiltrative tumors.
Purpose of the Study:
- To investigate diffusion MRI for early detection and characterization of slow-growing, diffuse infiltrative gliomas using LN-2669GS and LN-2540GS xenograft models.
- To optimize diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) protocols for enhanced contrast.
Main Methods:
- Utilized LN-2669GS and LN-2540GS glioma sphere xenografts in mice.
- Optimized DWI and DTI protocols using long diffusion times.
- Compared diffusion MRI findings with conventional MRI (T2-weighted), proton MR spectroscopy, and immunohistochemistry.
Main Results:
- Tumors invisible on conventional MRI were identified at an early stage using diffusion MRI.
- Diffusion MRI revealed tumor presence three months post-implantation, prior to necrosis or edema detection.
- Distinct diffusion indices (mean diffusivity, fractional anisotropy) were observed between LN-2669GS and LN-2540GS xenografts, reflecting diverse microstructures.
Conclusions:
- Diffusion MRI techniques can effectively identify and characterize early-stage, slow-growing, invasive gliomas in mouse models.
- Diffusion MRI shows promise as a non-invasive imaging biomarker for the early detection of brain tumors in humans.
More Related Videos
12:24Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
